Background: Present study was done with the objective to compare the change in the Iron Profile after Intravenous Ferric Carboxymaltose and Iron Sucrose in the treatment of Iron Deficiency Anemia in Pregnancy. Material and Methods: This was a prospective study conducted in the department of Obstetrics and Gynecology, IGMC, Shimla from 1st June 2019 to 31st May 2020.86 antenatal women with iron deficiency anemia were included and randomized into 2 equal groups with one group received intravenous FCM whereas another group received ISC. Results: The baseline value of hemoglobin, packed cell volume, serum iron, serum ferritin and total iron binding capacity were comparable in both the groups. All the subjects developed reticulocytosis following treatment with FCM and ISC, but the rise was significantly higher in FCM group as compared to ISC (2.9% versus 2.5% respectively at 4 weeks). At 2 weeks the mean hemoglobin was 10.48 g/dL in FCM group and 10.03 g/dL in ISC group. At 4 weeks the mean hemoglobin was 11.42 g/dL in FCM group and 11.00 g/dL in ISC group. The mean value in PCV at 2 weeks of follow up was 33.64 % in FCM group and 31.02 % in ISC group. At 4 weeks the mean PCV was 37.11% in FCM group whereas it was 34.17% in ISC group. Mean serum iron at 2 weeks was 114.67 ug/dl in FCM group and 92.75 ug/dl in ISC group. At 4 weeks mean serum iron was 137.95 ug/dL in FCM group compared to 111.03 ug/dl in ISC group. At 2 weeks, the levels of mean serum ferritin was 135.3 ng/mL in FCM group and 116.4 ng/mL in ISC group. At 4 weeks, the levels of mean serum ferritin were higher in FCM group compared to ISC group (107 ng/mL versus 96.3 ng/mL) respectively. At 4 weeks there was a significant fall in TIBC in those subjects who were treated with FCM compared to ISC (155.97 ug/dL versus 112.92 ug/dL respectively). Conclusion: There was very strong evidence against null hypothesis and there was significant difference in all the parameters in group A as compared to group B (p-value<0.001).